You are here

Development of Novel Broad Spectrum Antimicrobial Corneal Tissue Storage Solutions

Award Information
Agency: Department of Health and Human Services
Branch: Centers for Disease Control and Prevention
Contract: 75D30118PO2701
Agency Tracking Number: 75D30118PO2701
Amount: $149,858.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: ODCDC
Solicitation Number: N/A
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2415 N. Triphammer Rd
Ithaca, NY 14850
United States
DUNS: 824978477
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Nina Bionda
 (607) 330-2307
Business Contact
 Nina Bionda
Phone: (607) 330-2307
Research Institution

Endophthalmitis is a severe condition caused by inflammation of the ocular cavity and is a significant complication of corneal transplant proceduresoften being caused by microbial contamination of the donor tissueThe introduction of antibiotics into corneal tissue storage solutions in thes drastically lowered the incidence of bacterial endophthalmitis has drastically decreasedhoweverfungal endophthalmitisis on the riseThusthere is a clear need for the development of new corneal tissue storage products that prevent both bacterial and fungal microbial contaminationswhile still preserving the integrity of the corneal tissueiFyberthe lead organization for this effort proposes to evaluate multiple FDA approved antifungal agentsboth alone and combination with other antimicrobials to assess potential synergistic and or antagonistic effects with gentamicinstreptomycinand other broad spectrum antibioticsiFyber will make use of high throughput screening techniques to assess efficacy of these combination treatmentsand will also use an innovativeD human corneal tissue model to screen for potential effects on corneal tissue during storageTogetherthese tools will help to identify suitable formulation for corneal tissue storage solutionswhich will be further down selected in in vivo ocular irritation studies and transition into Phase II advanced development

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government